Left Ventricular Thrombus Clinical Trial
Official title:
Apixaban in Patients With Left Ventricular Thrombus Post Myocardial Infarction; A Randomized Clinical Trial
Open label randomized controlled clinical trial to evaluate the efficacy and safety of apixaban versus warfarin in treating left ventricular thrombus in patients with acute or recent myocardial infarction (MI).
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05077683 -
Direct Oral Anticoagulants for Prevention of lEft ventRIcular Thrombus After Anterior Acute Myocardial InFarction - APERITIF
|
Phase 3 | |
Recruiting |
NCT05973188 -
Safety and Efficacy of Rivaroxaban and Apixaban in Comparison to Warfarin in Left Ventricular Clot- Clinical Trial
|
Phase 4 | |
Recruiting |
NCT05892042 -
Anti-CoagulaTion on Left Ventricular Thrombus After ST Segment Elevation Myocardial Infarction
|
N/A | |
Recruiting |
NCT04970576 -
Rivaroxaban in Left Ventricular Thrombus
|
Phase 4 | |
Not yet recruiting |
NCT03415386 -
Optimized Antithrombotic Therapy of Acute Myocardial Infarction With Left Ventricular Mural Thrombus
|
Phase 4 | |
Recruiting |
NCT05794399 -
Anticoagulation in Post MI LV Thrombus Trial in Nepal
|
Phase 4 | |
Completed |
NCT05705089 -
Rivaroxaban vErsus Warfarin for Antithrombotic TheRapy in Patients With LeFt Ventricular Thrombus After Acute STEMI
|
Phase 3 | |
Not yet recruiting |
NCT06152939 -
Relation of Laboratory Indices to Left Ventricular Thrombus Formation in Patients With Acute Anterior ST Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention or Thrombolytic Therapy
|
||
Completed |
NCT04871126 -
Predictive Value of Inflammatory Indexes and CHA2DS2-VASc Score for LVT in ANT-MI With Left Ventricular Dysfunction
|
||
Recruiting |
NCT03764241 -
Treatment of Post-STEMI Left Ventricular Thrombus With Optimized Anticoagulant
|
Phase 3 | |
Recruiting |
NCT04829825 -
The "MyoThrombus" Study
|
||
Not yet recruiting |
NCT03786757 -
Prevention of Post-STEMI Left Ventricular Thrombus With Optimized Anticoagulant (EARLYmyo-LVT Ⅱ)
|
Phase 3 |